Af­ter be­ing re­peat­ed­ly jilt­ed, this biotech was swept off its feet in a race to ASH: In­side Mer­ck­'s $2.7B Ar­Qule buy­out

Over a pe­ri­od of more than a year, the ex­ecs at Ar­Qule had one fling af­ter the next with po­ten­tial part­ners, but ei­ther got left at the deal al­tar or were jilt­ed by cheap suit­ors. Then Mer­ck stepped in and swept them up with a short, in­tense round of ne­go­ti­a­tions in the lead-up to ASH.

Ar­Qule had plen­ty of dis­ap­point­ments to con­tend with along the way.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.